In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A). This evidence concerns the gene CD34 and metabolic dysfunction-associated steatohepatitis.